HC Wainwright & Co. Reiterates Neutral on Fulcrum Therapeutics, Maintains $5 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Andrew Fein has reiterated a Neutral rating on Fulcrum Therapeutics (NASDAQ:FULC) and maintained a $5 price target.
August 04, 2023 | 3:19 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
HC Wainwright & Co. has reiterated a Neutral rating on Fulcrum Therapeutics and maintained a $5 price target.
The reiteration of a Neutral rating and a $5 price target by HC Wainwright & Co. indicates that the analyst sees no significant changes in the company's outlook. This could mean that the stock price is expected to remain stable in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100